Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer

Nivolumab is an antiprogrammed death-1 (PD-1) antibody used for immuno-oncological therapy of various cancers, including nonsmall cell lung cancer (NSCLC). This study aimed to characterize the real-world population pharmacokinetics (PK) of nivolumab in patients with NSCLC. METHODS: PK samples were c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tohi, Makiko, Irie, Kei, Mizuno, Tomoyuki, Okuyoshi, Hiroyuki, Hirabatake, Masaki, Ikesue, Hiroaki, Muroi, Nobuyuki, Eto, Masaaki, Fukushima, Shoji, Tomii, Keisuke, Hashida, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819210/
https://www.ncbi.nlm.nih.gov/pubmed/35830878
http://dx.doi.org/10.1097/FTD.0000000000000996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819210/
https://www.ncbi.nlm.nih.gov/pubmed/35830878
http://dx.doi.org/10.1097/FTD.0000000000000996

Ejemplares similares